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Abstract
Familial Mediterranean fever (FMF) is caused by dysfunction of the MEFV gene product, pyrin.　
Here we report a case of FMF phenotype which developed into rheumatoid arthritis (RA), based on 
a positive result for anti-cyclic citrullinated peptide (CCP) antibody (Ab). A 42-year-old woman 
presented to our clinic with more than 6 months of intermittent arthralgia in the wrists, feet, and 
fingers associated with menstruation. No fever was reported and there was no family history of 
FMF or other autoimmune diseases. Laboratory tests revealed elevated C-reactive protein (CRP) 
and rheumatoid factor (RF). Tests for autoantibodies including anti-CCP Ab, antinuclear Ab, and 
anti-DNA Ab were all negative. Genetic analysis identified an R304R homozygous mutation in 
MEFV ; however, the pathological significance is unclear because this mutation does not cause ami-
no acid substitution. We diagnosed incomplete FMF phenotype despite the lack of fever due to pe-
riodic arthritis, lack of autoantibodies, and complete resolution of arthritis following colchicine treat-
ment within a day. Several months later, increased stiffness and arthralgia persistently occurred in 
finger joints on both sides. Ultrasonography revealed synovitis at the metacarpophalangeal and 
metatarsophalangeal joints. Laboratory analysis revealed the patient to be positive for anti-CCP 
Ab. Therefore, we finally diagnosed RA. Her arthritis diminished following administration of 
methotrexate and salazosulfapyridine. We consider the possibility that pyrin dysfunction may have 
affected the acquired immunity, contributing to the onset of RA as an autoimmune disease. This is 
an interesting case of equivalent FMF progressing into RA and will be valuable to raise awareness of 
a continuum from autoinflammatory to autoimmune disease.
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Introduction
Autoinflammatory diseases are characterized by 
systemic inflammation such as fever and rash, which 
differentiates them from autoimmune diseases such 
as rheumatoid arthritis (RA) or infections1). In 
terms of pathology, autoinflammatory diseases are 
caused by innate immunity while autoimmune 
diseases are caused by adaptive immunity, meaning 
that the two disorders are on opposite ends of a 
disease spectrum even though they share many 
clinical characteristics.　Familial Mediterranean 
fever (FMF) is the most common autoinflammatory 
disease, characterized by recurrent attacks of fever 
and polyserositis2).　Recently, pyrin — encoded by 
the MEFV gene — has been revealed to be directly 
involved in inflammasome activation and enhance-
ment of interleukin (IL)-1β production3).　Genetic 
and clinical differences have been reported between 
Japanese and non-Japanese patients with FMF, 
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indicating that a relationship exists between geno-
type and clinical phenotype4). It is common for 
FMF to co-exist with established rheumatic disease5) ; 
however, FMF phenotype in the context of RA is 
very rare.　We report the case of a patient with 
identical FMF who presented with joint synovitis in 
whom anti-cyclic citrullinated peptide (CCP) antibody 
(Ab) began to be detected during the disease course, 
with eventual progression into RA.
Case report
A 42-year-old woman presented with swelling 
of the dorsum in the left foot and intermittent 
arthralgia in both hands lasting for 6 months with no 
fever. Her medical history included a malignant 
sweat gland tumor in the head when she was 30 
years old. She had been previously diagnosed with 
iron deficiency anemia because of myoma uteri, for 
which she was taking iron supplements. No 
urinary tract infection or diarrhea had occurred 
before the onset of arthralgia.　The joint swelling 
and arthralgia only occurred during menstruation.　
She was referred to our clinic for further exami na-
tion with intermittent polyarthralgia.　She had no 
family history suggestive of FMF or other auto-
immune diseases including RA. Cardiovascular and 
respiratory examinations were unremarkable with 
no enlargement of the liver or spleen noted.　
However, physical examination revealed swelling 
and tenderness of the left foot as well as redness 
and tenderness in the metacarpophalangeal joint of 
the left thumb occurring only during menstruation.　
In addition, her arthritis was not a typical synovitis 
characterized as “fusiform swelling” that can be 
seen in RA, but rather, the swelling of an entire 
digit. No fever or oral ulcers were observed and 
blood tests showed normal hemoglobin levels and 
normal leukocyte and platelet counts. Laboratory 
tests revealed C-reactive protein and rheumatoid 
factor levels to be elevated (0.41 mg/dL and 64 IU/
mL, respectively). Anti-CCP Ab, anti-nuclear Ab 
(ANA), anti-DNA Ab, anti-SS-A Ab, anti-aminoacyl 
tRNA synthetase Ab, myeloperoxidase (MPO)-anti-
neutrophil cytoplasmic Ab (MPO-ANCA), and 
proteinase-3 (PR3)-ANCA were all negative.　
Immunoglobulin G (IgG), IgA, IgM, and IgD levels 
were normal and parvovirus B19-IgM was negative.　
Urinalysis showed no proteinuria or occult blood.　
Genetic analysis revealed a R304R homozygous 
mutation in the MEFV  gene ; however,  the 
pathological significance is unclear because no amino 
acid substitution was identified. The patient did 
not fulfill  the EULAR/ACR 2010 criteria for 
classification of RA6) at that time.　Following 
colchicine treatment (0.5 mg/day), the arthritis 
entirely disappeared within a day. Then, we applied 
international Tel-Hashmer crititeria by Livneh et 
al.7) to the present case, matching two minor criteria, 
including arthritis and favorable response to 
colchicine. Therefore, despite the lack of fever, we 
diagnosed equivalent incomplete FMF phenotype, 
based on periodic arthritis, complete disappearance 
of arthritis within a day of initiating oral colchicine 
treatment, and lack of autoantibodies. Four months 
later, stiffness and arthralgia persistently developed 
in some joints despite colchicine treatment up to 1.5 
mg/day, and each joint was also fusiform ; therefore, 
we performed ultrasonographic examination which 
revealed synovitis including the second metacar-
pophalangeal joints of the right side and the first 
metatarsophalangeal joints of both sides (Figure 1). 
Because of the observation of typical synovitis, we 
assayed anti-CCP Ab again, which was positive at 
this time (titer 11.2 U/mL). Therefore, the 
diagnosis of RA emerging from FMF phenotype was 
made at that time because the symptoms fulfilled 
the EULAR/ACR 2010 criteria for classification of 
RA including anti-CCP Ab positivity6). Treatment 
with 5 mg/day prednisolone, methotrexate, and 
salazosulfapyridine was initiated, and arthritis 
improved within two months.
Discussion
The pathology of FMF is caused by dysregula-
tion of inflammation due to abnormal function of the 
protein pyrin. Patients with FMF develop many 
clinical manifestations such as recurrent attacks of 
fever, periodic arthritis, and polyserositis. The 
most characteristic symptom is recurrent fever 
attacks of more than 38°C lasting several days. The 
condition usually affects pre-adolescent individuals8) ; 
however, a Japanese nationwide survey9) found the 
mean age at onset of clinical symptoms to be 19.6 ± 
15.3 years in Japanese patients, with around one-
third of patients (37.3%) experienced their first 
attack after they were 20 years old, indicating that 
Japanese patients with FMF develop their clinical 
manifestations later compared to non-Japanese 
cohorts. In the present case, the age of onset was 
42 years, which is similar to that in Japanese patients 
with FMF. Migita et al. reported the incidence of 
fever, chest pain as a result of pleuritis, and arthritis 
in FMF among a mainly Japanese cohort to be 
95.5%, 35%, and 31.3%, respectively10), which was 
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comparable to reports from non-Japanese cohorts11).　
It should be noted that about 5% of Japanese FMF 
patients are afebrile. In contrast, the prevalence of 
abdominal pain as a result of peritonitis and AA 
amyloidosis are higher in non-Japanese than 
Japanese patients with FMF. Arthritis is one of the 
common clinical features of FMF ; therefore, the 
possibility of FMF should be considered in patients 
presenting with arthritis, especially in the absence 
of RF or anti-CCP Ab, regardless of ethnicity.　
However, the diagnostic criteria vary for different 
populations ;  the Japanese criteria are based upon 
modified Tel-Hashmer criteria, which are simplified 
from the diagnostic criteria proposed by Migita’s 
group9), which include one major criterion (recurrent 
febrile episodes) and eight minor criteria (febrile 
attack with abdominal pain from peritonitis, chest 
pain from pleuritis, monoarthritis, pericarditis, 
scrotal pain from orchitis, headache from aseptic 
meningitis, or a favorable response to colchicine 
treatment). On the other hand, the Livneh’s 
criteria7), also derived from Tel-Hashmer criteria, 
provide an established international diagnosis of 
FMF. Importantly, in contrast to the Japanese 
criteria, periodic fever is not required for diagnosis 
of FMF in Livneh’s criteria. Livneh’s criteria are 
based on for major criteria involving typical attacks 
(peritonitis, pleuritis or pericarditis, monoarthritis, 
and fever) and five minor criteria involving 
incomplete attacks (abdomen, chest, joint, exertional 
leg pain, and favorable response to colchicine). If 
the patient fulfills two minor criteria, we can 
diagnose incomplete FMF even without periodic 
fever.　Moreover, a diagnosis of FMF also should be 
concluded after exclusion of differential diagnoses 
such as infection, malignancy, or other autoinflam-
matory disease. It is highly important that a 
diagnosis of FMF be based on clinical manifestations, 
not solely genetic analysis, according to EULAR 
recommendations12). Mindful that this case was 
afebrile, we diagnosed equivalent incomplete FMF 
by Livneh’s criteria, since the patient had arthritis 
that rapidly resolved following colchicine treatment.
It remains unclear why the present case was 
afebrile during the disease course ; however, FMF 
without fever has been described in several case 
reports13-15). It may be that dysfunction of co-
factors such as microsomal prostaglandin E 
synthase-1 (mPGES-1), a terminal enzyme required 
for PGE2 synthesis, may suppress fever as pro-
inflammatory cytokines are necessary for febrile 
response. An in vivo study demonstrated that 
l ipopolysaccharide (LPS)-stimulated febrile 
response is attenuated in chimeric mice when 
mPGES-1 expression is restricted to hematopoietic 
cells16). Thus, the synergistic actions of IL-1β, IL-
6, and mPGES1 in non-hematopoietic cells regulate 
the LPS-induced febrile response. In our case, 
Figure 1. Ultrasound examination showed thickened synovium by Power Doppler, indicating synovitis.
 (a) Ultrasound image of the second metacarpophalangeal joints on the right side (arrowheads indicate synovial 
thickening).
 (b) Ultrasound image of the first metatarsophalangeal joints on both sides (arrowheads indicate synovial thicken-
ing).
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insufficient expression of mPGES-1 in non-hemato-
poietic cells may have resulted in the afebrile pre-
sentation ;  however, further investigation is requi-
red to elucidate the exact mechanisms under lying 
the lack of fever in FMF.
The present case experienced recurrent arthri-
tis but joint swelling and pain was completely absent 
when she was not menstruating. This phenomenon 
is an important indicator of FMF, because menstru a-
tion is known to be a trigger for clinical attacks of 
FMF17). Therefore, in cases such as ours, the 
patient’s arthralgia can be characterized as FMF-
related arthropathy.
This case had a homozygous mutation of MEFV 
(R304R), which does not cause amino acid substi tu-
tion.　The MEFV gene is responsible for FMF18) 
and more than 300 sequence variants have been 
identified19) ; of the 14 reported in 2012, nine are 
pathogenic and five have unknown significance20).　It 
has been reported that 86.5% of Japanese patients 
with FMF have one or more MEFV mutations or 
polymorphisms, the most frequent being M694I/
E148Q (19.8%)10). However, about 15% of Japanese 
FMF patients have no MEFV mutations. On the 
other hand, the frequency of the MEFV mutations in 
RA has been reported by Migita’s group21). They 
demonstrated that allele frequencies of R408Q, 
P369S, E148Q, L110P mutations account respec-
tively for 5.6%, 6.7%, 24.2%, 9.5% in RA patients 
and that the overall mutation rate was comparable 
between RA and healthy controls, indicating that 
MEFV mutations are not rare in RA.　Their findings 
also suggest that MEFV mutations could not be a 
genetic factor affecting the susceptibility to RA. In 
addition, most importantly, recommendations allow a 
diagnosis of FMF even without MEFV mutations12). 
Based on these factors, it is possible to diagnose our 
case as FMF phenotype.
Migita et al. reported that, among 192 Japanese 
patients with FMF, 26 (13.5%) experienced 
accompanying rheumatic diseases5). While the 
coexistence of autoinflammatory and autoimmune 
diseases is not rare22), reports of coexisting FMF and 
RA are relatively rare23), with anti-CCP Ab-positive 
RA being par t icularly rare.  Monoarthrit is 
associated with FMF usually occurs in large joints 
such as the knee or hip and protracted arthritis is 
rare24), in contrast with early RA where polyarthritis 
frequently develops in the hand or ankle. On the 
other hand, Endo et al. reported that late-onset FMF 
patients with onset ≧40 years present significantly 
more frequently with arthritis and myalgia compared 
to those with onset <40 years25). The present case 
is also late-onset FMF phenotype, therefore 
occurring predominantly with arthritis, consistent 
with Endo’s report.
Our case exhibited symmetrical arthritis of the 
finger and ankle that resolved with colchicine 
treatment in early phase, with ultrasonographic 
evidence of synovitis in the joint, which is an 
important indicator of early RA26) in late phase.　
However, the present case did not fulfill the EULAR/
ACR 2010 classification criteria for early RA without 
anti-CCP Ab positivity in early phase. When the 
present case developed arthritis just intermittently, 
each joint exhibited swelling of an entire digit, which 
made it hard precisely localize synovitis. EULAR/
ACR 2010 criteria6) refer to target patients who have 
at least 1 joint with “definitive clinical synovitis”.　
Therefore, the present case was not classifiable as 
having RA with a score < 6/10 (namely, presence of 
high titers of RF, and elevated levels of CRP).　
There are very few reports investigating the associ-
ation FMF with RF positivity. Guler et al.27) showed 
that the proportion of RF-positive FMF was 4% 
although the number of patients was small.　They 
also demonstrated that RF positivity was not differ-
ent between FMF and healthy controls.
The anti-CCP Ab is a highly specific biomarker 
for RA (>95% specificity) that indicates a high risk 
of progressive joint destruction28). A case complicated 
by anti-CCP Ab-positive RA and FMF has been 
reported by Migita et al.23). In their case, arthritis 
refractory to conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs) was 
completely improved by using colchicine. The 
relationship between FMF and anti-CCP Ab is 
controversial. One study reported a relationship 
between FMF and anti-CCP Ab29), while another 
study reported no such relationship30).　Importantly, 
Karatay’s report demonstrated that anti-CCP Ab 
was negative in all FMF patients30).　However, 
arthritis caused by FMF may disappear with 
colchicine treatment. In our case, arthritis in early 
phase was temporarily resolved by colchicine.　In 
contrast, arthritis was refractory to colchicine after 
anti-CCP Ab was detected, and csDMARDs such as 
MTX were effective. Moreover, each joint swelling 
became “fusiform,” which is typical  for RA 
synovitis. Therefore, we diagnosed RA when anti-
CCP Ab positivity was observed. This change in 
antibody status presents an interesting case where 
RA developed and overlapped with equivalent FMF ; 
recently, “autoinflammatory-autoimmune contin-
uum” has been reported as a new disease spec-
trum31). Autoinflammatory diseases are systemic 
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disorders caused by dysregulations of innate 
immunity32), whereas autoimmune disorders are 
caused by dysregulation of adaptive immunity.　
However, symptoms of systemic juvenile idiopathic 
arthritis often include fever and polyarthritis, and 
genome-wide analysis has demonstrated that 
autoimmune arthritis can develop from a predom i-
nantly autoinflammatory disease phenotype33).　
Furthermore, patients with haploinsufficiency of A20 
(HA20), caused by heterozygous germline mutations 
in the TNFAIP3 gene, present with clinical manifes-
tations of autoinflammatory diseases such as Behçet 
disease, often coexisting with various autoimmune 
disorders34). Innate immunity is accelerated in 
RA35) ; for example, activation of the NLRP3 inflam-
masome, a major component of autoinflammatory 
pathogenesis, reportedly contributes to autoinflam-
matory diseases36) as well as autoimmune diseases 
including RA37).
The mechanism underlying the development of 
RA in the present case is unclear ; one possible 
explanation is involvement of the “pyrin inflam-
masome,” which is a recently proposed concept 
suggesting that pyrin directly enhances inflamma-
tion3,38,39) following inactivation of Rho GTPases by 
bacterial toxins and other effectors, leading to 
dephosphorylation of pyrin. As a result, the 14-3-3 
protein disassociates from pre-active pyrin resulting 
in pyrin activation. The inflammasome is then 
activated through polymerization of activated pyrin 
and apoptosis-associated speck-like protein contain-
ing a CARD (ASC). Finally, the pyrin inflam-
masome induces IL-1β production and inflam-
mation. Thus, pyrin may function as a sensor of 
inactivation of Rho GTPases induced by pathogens 
like intestinal flora.
Patients with FMF could be more sensitive to 
dysbiosis (disturbance of intestinal bacterial flora 
and loss of protection from various pathogens), 
provoking systemic innate or adaptive immunity 
involving intestinal epithelial cells and other immune 
cells40). Indeed, dysbiosis has been detected in 
patients with RA41), as dysbiosis can lead to post-
translational modification of autoantibodies and 
subsequent development of  RA42,43).  Thus, 
dysbiosis of gut bacteria could drive adaptive immu-
nity and autoimmunity leading to RA and innate 
immunity leading to FMF.
We encountered a rare case of equivalent FMF 
which developed to RA, providing an interesting 
“hybrid” phenotype which cannot be classified as a 
purely autoinflammatory or autoimmune disease.　
Furthermore, our findings suggest that therapy for 
RA should be decided according to the conditions 
which induce the progression to autoinflammatory 
or autoimmune disease, especially when biological 
agents are considered. For example, the IL-6 
inhibitor tocilizumab has been reported to be 
beneficial for colchicine-resistant FMF as well as 
RA among Japanese patients44). The present case 
adds valuable information to current knowledge 
relating to pathophysiological categorization of 
autoinflammatory and autoimmune disorders.
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